Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879136 | 0.82 | NNMT (0.34) | NNMTLRRK2KAT2BBRD9ALDH1A1 | |
| SCHEMBL16187963 | 0.80 | ALDH1A1 (0.36) | NNMTLRRK2KAT2BBRD9ALDH1A1 | |
| SCHEMBL12102878 | 0.80 | NNMT (0.49) | NNMTLRRK2KAT2BBRD9JAK2 | |
| SCHEMBL20931323 | 0.80 | SLC6A2 (0.36) | NNMTLRRK2KAT2BBRD9JAK2 | |
| SCHEMBL19462480 | 0.78 | TGFBR1 (0.38) | KAT2BBRD9 | |
| SCHEMBL14941507 | 0.78 | NNMT (0.33) | NNMTKAT2BBRD9ALDH1A1KDM4E | |
| SCHEMBL26598725 | 0.78 | LRRK2 (0.34) | LRRK2KAT2BBRD9 | |
| SCHEMBL18504878 | 0.78 | APP (0.33) | NNMTKAT2BBRD9ALDH1A1KDM4E | |
| SCHEMBL12456743 | 0.78 | UHRF1 (0.34) | NNMTKAT2BBRD9ALDH1A1KDM4E | |
| SCHEMBL12439072 | 0.76 | ALDH1A1 (0.36) | NNMTLRRK2KAT2BBRD9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776417-B1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECH LTD (GB) | 2018-10-31 | — | — | EP | disclosed |
| CN-104105696-B | The nitrile compound of 5 (the base amino of pyridine 2) pyrazine 2 and its therapeutical uses | 癌症研究技术有限公司 | 2017-11-14 | — | — | CN | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-9403797-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-02 | — | — | US | disclosed |
| US-9403797-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-02 | — | — | US | disclosed |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| EP-2776417-A1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | Cancer Research Technology Limited (GB) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068755-A1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013068755-A1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | NNMT 610/4885LRRK2 630/4885KAT2B 3737/4885 |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | NNMT 610/4885LRRK2 630/4885KAT2B 3737/4885 |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | NNMT 610/4885LRRK2 630/4885KAT2B 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.